Chinese capital accesses Western innovation to create homegrown industry

February 9, 2017 Christoph Graener

With the Chinese market growing at 10–15% a year, it is poised to be world’s largest by 2026. Tony Chu, co-founder and managing partner at consultants TPP Healthcare, explains to Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, how Chinese capital is accessing Western innovation to build a PRC pharma industry.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Tony Chu – Founding Partner, TPP Healthcare

Previous Article
Catabasis pursues bifunctional mutation-agnostic approach to DMD

Using its safely metabolized and rationally targeted (SMART) linker platform, Catabasis has identified an N...

Next Article
Advancing neurokinin receptor antagonists in respiratory and women’s health

Starting the year with a cash injection of GDP 23 million, NeRRe Therapeutics intends to advance its neurok...